Actively Recruiting
Evaluation of Oral Secutrelvir Compared to Placebo for Treatment of COVID-19 Symptoms in Nonhospitalized Participants
Led by Shionogi · Updated on 2026-09-02
1200
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of secutrelvir compared to a placebo in people aged 12 to 74 who have COVID-19 but are not hospitalized. The study focuses on how quickly clinical symptoms resolve when starting treatment within 48 hours of symptom onset. This Phase 3 study aims to understand the treatments safety and effectiveness in relieving COVID-19 symptoms. Participants will be randomly assigned to receive either secutrelvir or a placebo, both given as oral tablets. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment begins promptly within 48 hours of symptom start, and participants are monitored throughout the study period. During the study, participants will be regularly assessed for the resolution and alleviation of 14 specific COVID-19 symptoms, fever reduction, and viral levels in the body. Safety is monitored by tracking any treatment-emergent adverse events. The primary outcome measure is the time to first resolution of symptoms within 21 days. The study lasts until primary completion around July 2027 with follow-up assessments continuing through 28 days after treatment begins.
CONDITIONS
Brief Title
Study of Secutrelvir in Participants With COVID-19
Research Team
S
Shionogi Clinical Trials Administrator Clinical Support Help Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here